Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Philippe Van den Steen
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Anatomy
Concepts & Ideas
Phenomena
Living Beings
Physiology
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
47
Opdenakker, Ghislain
16
Van Damme, Jo
13
Proost, Paul
10
Rudd, Pauline
10
Dwek, Raymond
10
Martens, Erik
8
Hu, Jialiang
7
Wormald, Mark
6
Fiten, Pierre
5
Descamps, Francis
5
Starckx, Sofie
5
Piccard, Helene
5
Nelissen, Inge
5
Van Aelst, Ilse
4
Royle, Louise
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Philippe Van den Steen (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Ardi Veronica C; Van den Steen Philippe E; Opdenakker Ghislain; Schweighofer Bernhard; Deryugina Elena I; Quigley James P
Neutrophil MMP-9 proenzyme, unencumbered by TIMP-1, undergoes efficient activation in vivo and catalytically induces angiogenesis via a basic fibroblast growth factor (FGF-2)/FGFR-2 pathway.
The Journal of biological chemistry 2009;284(38):25854-66.
-
2009: Piccard Helene; Hu Jialiang; Fiten Pierre; Proost Paul; Martens Erik; Van den Steen Philippe E; Van Damme Jo; Opdenakker Ghislain
"Reverse degradomics", monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products.
Electrophoresis 2009;30(13):2366-77.
-
2009: Gioia Magda; Monaco Susanna; Van Den Steen Philippe E; Sbardella Diego; Grasso Giuseppe; Marini Stefano; Overall Christopher M; Opdenakker Ghislain; Coletta Massimo
The collagen binding domain of gelatinase A modulates degradation of collagen IV by gelatinase B.
Journal of molecular biology 2009;386(2):419-34.
-
2008: De Palma Armando M; Verbeken Erik; Van Aelst Ilse; Van den Steen Philippe E; Opdenakker Ghislain; Neyts Johan
Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis.
Virology 2008;382(1):20-7.
-
2008: Li Sandra; Martens Erik; Dillen Chris; Van den Steen Philippe E; Opdenakker Ghislain
Virus entry inhibition by chlorite-oxidized oxyamylose versus induction of antiviral interferon by poly(I:C).
Biochemical pharmacology 2008;76(7):831-40.
-
2008: Cauwe Bénédicte; Martens Erik; Van den Steen Philippe E; Proost Paul; Van Aelst Ilse; Blockmans Daniel; Opdenakker Ghislain
Adenylyl cyclase-associated protein-1/CAP1 as a biological target substrate of gelatinase B/MMP-9.
Experimental cell research 2008;314(15):2739-49.
-
2008: Redondo-Muñoz Javier; Ugarte-Berzal Estefanía; García-Marco José A; del Cerro Mercedes Hernández; Van den Steen Philippe E; Opdenakker Ghislain; Terol María José; García-Pardo Angeles
Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells.
Blood 2008;112(1):169-78.
-
2008: Van den Steen Philippe E; Deroost Katrien; Van Aelst Ilse; Geurts Nathalie; Martens Erik; Struyf Sofie; Nie Catherine Q; Hansen Diana S; Matthys Patrick; Van Damme Jo; Opdenakker Ghislain
CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines.
European journal of immunology 2008;38(4):1082-95.
-
2008: Muroski M E; Roycik M D; Newcomer R G; Van den Steen P E; Opdenakker G; Monroe H R; Sahab Z J; Sang Q-X
Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.
Current pharmaceutical biotechnology 2008;9(1):34-46.
-
2008: Geurts Nathalie; Martens Erik; Van Aelst Ilse; Proost Paul; Opdenakker Ghislain; Van den Steen Philippe E
Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3.
Biochemistry 2008;47(8):2689-99.
-
2007: Rosenblum Gabriel; Van den Steen Philippe E; Cohen Sidney R; Grossmann J Günter; Frenkel Jessica; Sertchook Rotem; Slack Nelle; Strange Richard W; Opdenakker Ghislain; Sagi Irit
Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B.
Structure (London, England : 1993) 2007;15(10):1227-36.
-
2007: Hu Jialiang; Van den Steen Philippe E; Sang Qing-Xiang A; Opdenakker Ghislain
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
Nature reviews. Drug discovery 2007;6(6):480-98.
-
2007: Cauwe Bénédicte; Van den Steen Philippe E; Opdenakker Ghislain
The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases.
Critical reviews in biochemistry and molecular biology 2007;42(3):113-85.
-
2007: Piccard Helene; Van den Steen Philippe E; Opdenakker Ghislain
Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins.
Journal of leukocyte biology 2007;81(4):870-92.
-
2007: Abu El-Asrar Ahmed M; Van den Steen Philippe E; Al-Amro Saleh A; Missotten Luc; Opdenakker Ghislain; Geboes Karel
Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders.
International ophthalmology 2007;27(1):11-22.
-
2007: Martens Erik; Leyssen An; Van Aelst Ilse; Fiten Pierre; Piccard Helene; Hu Jialiang; Descamps Francis J; Van den Steen Philippe E; Proost Paul; Van Damme Jo; Liuzzi Grazia Maria; Riccio Paolo; Polverini Eugenia; Opdenakker Ghislain
A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains.
Biochimica et biophysica acta 2007;1770(2):178-86.
-
2006: Fry Simon A; Van den Steen Philippe E; Royle Louise; Wormald Mark R; Leathem Anthony J; Opdenakker Ghislain; McDonnell James M; Dwek Raymond A; Rudd Pauline M
Cancer-associated glycoforms of gelatinase B exhibit a decreased level of binding to galectin-3.
Biochemistry 2006;45(51):15249-58.
-
2006: Hu Jialiang; Dubois Véronique; Chaltin Patrick; Fiten Pierre; Dillen Christiane; Van den Steen Philippe E; Opdenakker Ghislain
Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library.
Combinatorial chemistry & high throughput screening 2006;9(8):599-611.
-
2006: Van den Steen Philippe E; Van Aelst Ilse; Starckx Sofie; Maskos Klaus; Opdenakker Ghislain; Pagenstecher Axel
Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria.
Laboratory investigation; a journal of technical methods and pathology 2006;86(9):873-88.
-
2006: Van den Steen Philippe E; Van Aelst Ilse; Hvidberg Vibeke; Piccard Helene; Fiten Pierre; Jacobsen Christian; Moestrup Soren K; Fry Simon; Royle Louise; Wormald Mark R; Wallis Russell; Rudd Pauline M; Dwek Raymond A; Opdenakker Ghislain
The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors.
The Journal of biological chemistry 2006;281(27):18626-37.
-
2006: Opdenakker Ghislain; Dillen Chris; Fiten Pierre; Martens Erik; Van Aelst Ilse; Van den Steen Philippe E; Nelissen Inge; Starckx Sofie; Descamps Francis J; Hu Jialiang; Piccard Helene; Van Damme Jo; Wormald Mark R; Rudd Pauline M; Dwek Raymond A
Remnant epitopes, autoimmunity and glycosylation.
Biochimica et biophysica acta 2006;1760(4):610-5.
-
2005: Hu Jialiang; Van den Steen Philippe E; Dillen Chris; Opdenakker Ghislain
Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock.
Biochemical pharmacology 2005;70(4):535-44.
-
2005: Hu Jialiang; Fiten Pierre; Van den Steen Philippe E; Chaltin Patrick; Opdenakker Ghislain
Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform.
Analytical chemistry 2005;77(7):2116-24.
-
2005: Descamps Francis J; Martens Erik; Proost Paul; Starckx Sofie; Van den Steen Philippe E; Van Damme Jo; Opdenakker Ghislain
Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(1):29-35.
-
2005: Fry Simon A; Van den Steen Philippe E; Royle Louise; Wormald Mark R; Leathem Anthony J; Opdenakker Ghislain; Rudd Pauline M; Dwek Raymond A
Differential glycosylation of gelatinase B from neutrophils and breast cancer cells.
Advances in experimental medicine and biology 2005;564():103-12.
-
2005: Van den Steen P E; Grillet B; Opdenakker G
Gelatinase B participates in collagen II degradation and releases glycosylated remnant epitopes in rheumatoid arthritis.
Advances in experimental medicine and biology 2005;564():45-55.
-
2004: Van den Steen P E; Proost P; Brand D D; Kang A H; Van Damme J; Opdenakker G
Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B.
Biochemistry 2004;43(33):10809-16.
-
2004: Hu Jialiang; Van den Steen Philippe E; Houde Michel; Ilenchuk T Toney; Opdenakker Ghislain
Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody.
Biochemical pharmacology 2004;67(5):1001-9.
-
2003: Van den Steen Philippe E; Husson Steven J; Proost Paul; Van Damme Jo; Opdenakker Ghislain
Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase.
Biochemical and biophysical research communications 2003;310(3):889-96.
-
2003: Van Den Steen Philippe E; Wuyts Anja; Husson Steven J; Proost Paul; Van Damme Jo; Opdenakker Ghislain
Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities.
European journal of biochemistry / FEBS 2003;270(18):3739-49.
-
2003: Starckx Sofie; Van den Steen Philippe E; Verbeek Richard; van Noort Johannes M; Opdenakker Ghislain
A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope.
Journal of neuroimmunology 2003;141(1-2):47-57.
-
2003: Nelissen Inge; Martens Erik; Van den Steen Philippe E; Proost Paul; Ronsse Isabelle; Opdenakker Ghislain
Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy.
Brain : a journal of neurology 2003;126(Pt 6):1371-81.
-
2003: Descamps Francis J; Van den Steen Philippe E; Martens Erik; Ballaux Florence; Geboes Karel; Opdenakker Ghislain
Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(8):887-9.
-
2003: Opdenakker Ghislain; Van den Steen Philippe E; Laureys Geneviève; Hunninck Kathleen; Arnold Bernd
Neutralizing antibodies in gene-defective hosts.
Trends in immunology 2003;24(2):94-100.
-
2003: Descamps Francis J; Van den Steen Philippe E; Nelissen Inge; Van Damme Jo; Opdenakker Ghislain
Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes.
Advances in experimental medicine and biology 2003;535():69-77.
-
2002: Van den Steen Philippe E; Dubois Bénédicte; Nelissen Inge; Rudd Pauline M; Dwek Raymond A; Opdenakker Ghislain
Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9).
Critical reviews in biochemistry and molecular biology 2002;37(6):375-536.
-
2002: Van den Steen Philippe E; Proost Paul; Grillet Bernard; Brand David D; Kang Andrew H; Van Damme Jo; Opdenakker Ghislain
Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(3):379-89.
-
2002: Starckx S; Van den Steen P E; Wuyts A; Van Damme J; Opdenakker G
Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization.
Leukemia & lymphoma 2002;43(2):233-41.
-
2001: Van den Steen P E; Opdenakker G; Wormald M R; Dwek R A; Rudd P M
Matrix remodelling enzymes, the protease cascade and glycosylation.
Biochimica et biophysica acta 2001;1528(2-3):61-73.
-
2001: Opdenakker G; Van den Steen P E; Van Damme J
Gelatinase B: a tuner and amplifier of immune functions.
Trends in immunology 2001;22(10):571-9.
-
2001: Opdenakker G; Van den Steen P E; Dubois B; Nelissen I; Van Coillie E; Masure S; Proost P; Van Damme J
Gelatinase B functions as regulator and effector in leukocyte biology.
Journal of leukocyte biology 2001;69(6):851-9.
-
2000: Mattu T S; Royle L; Langridge J; Wormald M R; Van den Steen P E; Van Damme J; Opdenakker G; Harvey D J; Dwek R A; Rudd P M
O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme.
Biochemistry 2000;39(51):15695-704.
-
2000: Kleifeld O; Van den Steen P E; Frenkel A; Cheng F; Jiang H L; Opdenakker G; Sagi I
Structural characterization of the catalytic active site in the latent and active natural gelatinase B from human neutrophils.
The Journal of biological chemistry 2000;275(44):34335-43.
-
2000: Van den Steen P E; Proost P; Wuyts A; Van Damme J; Opdenakker G
Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.
Blood 2000;96(8):2673-81.
-
1999: Rudd P M; Mattu T S; Masure S; Bratt T; Van den Steen P E; Wormald M R; Küster B; Harvey D J; Borregaard N; Van Damme J; Dwek R A; Opdenakker G
Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin.
Biochemistry 1999;38(42):13937-50.
-
1998: Van den Steen P; Rudd P M; Proost P; Martens E; Paemen L; Küster B; van Damme J; Dwek R A; Opdenakker G
Oligosaccharides of recombinant mouse gelatinase B variants.
Biochimica et biophysica acta 1998;1425(3):587-98.
-
1998: Van den Steen P; Rudd P M; Dwek R A; Opdenakker G
Concepts and principles of O-linked glycosylation.
Critical reviews in biochemistry and molecular biology 1998;33(3):151-208.
-
1998: Van den Steen P; Rudd P M; Dwek R A; Van Damme J; Opdenakker G
Cytokine and protease glycosylation as a regulatory mechanism in inflammation and autoimmunity.
Advances in experimental medicine and biology 1998;435():133-43.
-
1989: Heirwegh K P; Meuwissen J A; Van den Steen P; De Smedt H
Modelling of chemical reactions catalysed by membrane-bound enzymes. Determination and significance of the kinetic constants.
Biochimica et biophysica acta 1989;995(2):151-9.
Sign-in to see more
